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ABSTRACT
AMP-activated protein kinase (AMPK) is a heterotrimeric complex, composed of a catalytic subunit (α) and two regulatory subunits (β and γ), which acts as a metabolic sensor to regulate glucose and lipid metabolism. A mutation in the γ3-subunit (AMPKγ3 R225Q ) increases basal AMPK phosphorylation, while concomitantly reducing sensitivity to AMP. AMPKγ3 R225Q transgenic mice are protected against dietary-induced triglyceride accumulation and insulin resistance. We determined whether skeletal muscle-specific expression of AMPKγ3 R225Q prevents metabolic abnormalities in leptin-deficient ob/ob mice (ob/ob-γ3 R225Q ). Glycogen content was increased, triglyceride content was decreased and diacylglycerol and ceramide content was unaltered in gastrocnemius muscle from ob/ob-γ3 R225Q mice, whereas glucose tolerance was unaltered. Insulin-stimulated glucose uptake in extensor digitorum longus muscle during the euglycemic-hyperinsulinemic clamp was increased in lean γ3 R225Q mice, but not in ob/ob-γ3 R225Q mice. Acetyl-CoA carboxylase phosphorylation was increased in gastrocnemius muscle from γ3 R225Q mutant mice independent of adiposity. Glycogen and triglyceride content was decreased after leptin treatment (5 days) in ob/ob mice, but not ob/ob-γ3 R225Q mice. In conclusion, metabolic improvements arising from muscle-specific expression of AMPKγ3 R225Q are insufficient to ameliorate insulin resistance and obesity in leptin-deficient mice. Central defects due to leptin deficiency may override any metabolic benefit conferred by peripheral overexpression of the AMPKγ3 R225Q mutation.
AMP-activated protein kinase (AMPK) is a heterotrimeric complex, composed of a catalytic subunit (α1 or α2) and two regulatory subunits (β1 or β2 and γ1, γ2 or γ3), which acts as a metabolic sensor to regulate glucose and lipid metabolism (1) . AMPK is activated in response to changes in the intracellular AMP/ATP and ADP/ATP ratios in response to cellular stress or nutrient deprivation, changes in calcium concentration, or alterations in circulating levels of various hormones including leptin, cytokines or adiponectin (2, 3) . Several lines of evidence highlight AMPK as an inter-tissue signal integrator among peripheral tissues and the hypothalamus to control whole-body energy and glucose homeostasis (4) (5) (6) (7) (8) (9) (10) .
Acute activation of AMPK in peripheral tissues stimulates glucose uptake and lipid oxidation to produce energy, while turning off energy-consuming processes including synthesis of glycogen, lipids and proteins (2) . Pharmacological activation of AMPK in rodents or humans with insulin resistance or type 2 diabetes increases skeletal muscle glucose uptake (5, 7, 11, 12) by an insulin-independent mechanism (13) . Although AMPK can form up to 12 unique heterotrimeric complexes based on the expression of different α/β/γ subunits, only three complexes (α1/β2/γ1, α2/β2/γ1and α2/β2/γ3) are found in human skeletal muscle (14) . Expression profiling of the AMPK γ-subunits in human and rodent skeletal muscle highlights a specialized role for the γ3 isoform in glycolytic fibers (15) . Expression of a naturally occurring mutant (R225Q) form of the AMPK γ3-subunit (16) in COS7 cells increases basal AMPK phosphorylation, while concomitantly reducing sensitivity to AMP (17) . Moreover, AMPKγ3 R225Q transgenic mice have increased glycogen content, enhanced mitochondrial biogenesis and are protected against dietary-induced triglyceride accumulation and insulin resistance in glycolytic skeletal muscle (17, 18) . This phenotype is copied in humans expressing the rare AMPKγ3 R225W mutation, which increases basal AMPK activity and muscle glycogen content and decreases intramuscular triglyceride levels (19) . Thus, life-long expression of activated forms of AMPKγ3 may prevent disturbances in glucose and lipid homeostasis characteristic of obese people with insulin resistance or type 2 diabetes (20, 21) .
The hypothalamus is a master regulator of food intake and energy balance and coordinates glucose and energy homeostasis in response to the adipose-derived peripheral hormone leptin (22) . Hypothalamic AMPK signaling plays an important role in the regulation of food intake (4, 8, 9) . Activation of hypothalamic AMPK by counter-regulatory hormones involved in appetite control, as well as by pharmacological AMPK activators increase food intake (4, 9) . Conversely, leptin inhibits hypothalamic AMPK signaling to reduce food intake and body weight, and increases AMPK signaling in peripheral tissues to promote lipid oxidation (4) and deplete triglyceride stores (23, 24) . Thus, an appropriate balance between AMPK signaling in central and peripheral tissues appears to be important for glucose and energy homeostasis. Previously, we have provided evidence that muscle-specific AMPKγ3 R225Q transgenic mice rendered obese, and hyperleptinemic by a high fat diet are protected against excessive intramuscular triglyceride accumulation and the development of insulin resistance, presumably due to increased AMPK activation and lipid oxidation in skeletal muscle (17) . This raises the question of whether AMPK activation can improve defects in insulin action and metabolism arising from severe obesity from either leptin deficiency or impaired leptin signaling. For example, in severely obese diabetic leptin receptor-deficient db/db mice, glucose transporter (GLUT) 4 overexpression can improve glucose tolerance (25) , as well as skeletal muscle insulin sensitivity (26) . Furthermore, AMPK activation by 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) treatment improves glucose homeostasis in rodents (5, 7) . Given the important role of leptin on energy balance, we determined whether glucose and energy homeostasis are improved by skeletal muscle overexpression of the mutant AMPKγ3 R225Q subunit in leptin-deficient ob/ob mice and whether the effects of AMPK are leptin-dependent.
RESEARCH DESIGN AND METHODS

Reagents:
Reagents were purchased from Sigma-Aldrich (St Louis, MO), unless otherwise stated.
Animals:
Wild-type (WT) and skeletal muscle-specific AMPKγ3 R225Q (γ3
R225Q
) transgenic mice were generated as described (17) . Glycogen and triglyceride determination: Four-hour fasted mice were anesthetized with Avertin (2,2,2-tribromoethanol 99% and tertiary amyl alcohol (1:1 w/v), 500 mg/kg of body weight), gastrocnemius muscle and liver was removed, cleaned of fat and blood, and quickly frozen in liquid nitrogen. Glycogen content was determined fluorometrically on HCl extracts as described (17) . Triglyceride content was determined using a triglyceride/glycerol blanked kit (Roche Diagnostics Scandinavia AB, Sweden) using Seronorm TM lipid as a standard (17) .
Intraperitoneal glucose tolerance test (IPGTT):
Animals were fasted for four hours and basal glucose levels were measured using OneTouch Ultra glucose meter (Lifescan, Milpitas, CA (27) . Results are reported as ng glucose/mg/min.
Lipid oxidation in isolated skeletal muscle: Palmitate oxidation in isolated EDL muscle was analyzed as described (28) . EDL muscles were incubated in a Krebs-Henseleit buffer. After recovery, muscles were incubated for two hours in 3 H-palmitate (Perkin Elmer). Palmitate oxidation was determined by analyzing the 3 H-labeled water content using liquid scintillation counting. Results are reported as pmol/mg/min.
Mitochondrial respiration:
Mitochondrial respiration in freshly isolated EDL muscle was determined using high-resolution respirometry (Oxygraph-2k, Oroboros Instruments, Innsbruck, Austria) as described (29, 30) . EDL muscles were dissected out and fibers were gently separated under a microscope. Following saponin permeabilization in ice-cold relaxing and biopsy preservation solution (BIOPS), tissues were equilibrated in ice-cold mitochondrial respiration medium (MiRO5) and 1-2 mg of tissue was added to the respirometry chamber 
Statistics: Statistical analysis was performed by unpaired 2-tailed Student's t-test or two-way
ANOVA where applicable. The γ3 R225Q mice were compared with WT and the ob/ob-γ3 R225Q mice were compared with the ob/ob unless otherwise stated. The effect of leptin treatment was compared to saline treatment in the lean and obese models. Results were considered statistically significant at p<0.05.
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RESULTS
Glycogen content in skeletal muscle: Glycogen content was determined in gastrocnemius muscle from four-hour fasted WT, lean γ3 R225Q transgenic, ob/ob and ob/ob-γ3 R225Q transgenic mice. As previously reported (17) , the AMPKγ3 R225Q mutation increased glycogen content in lean mice (Fig. 1 ). WT and ob/ob mice have similar levels of glycogen content in gastrocnemius muscle. Consistent with the lean γ3 R225Q transgenic mice, glycogen content in gastrocnemius muscle was increased in ob/ob-γ3 R225Q transgenic mice compared to ob/ob mice ( Fig. 1 ).
Glucose tolerance in ob/ob-γ3 R225Q transgenic mice: Glucose tolerance was similar between ob/ob and ob/ob-γ3 R225Q transgenic mice ( Fig. 2A) , consistent with our previously observation that glucose tolerance is unaltered in lean WT and γ3 R225Q transgenic mice (17) . Plasma insulin concentrations determined at baseline and 15 min after the glucose injection were similar between the ob/ob and ob/ob-γ3 R225Q transgenic mice (Fig. 2B ).
In vivo insulin-stimulated glucose uptake in skeletal muscle: We performed a euglycemichyperinsulinemic clamp to assess in vivo glucose uptake in EDL and gastrocnemius muscle.
Lean WT and γ3 R225Q transgenic mice were clamped using an insulin infusion of 10 mU/kg/min (Basal plasma insulin levels were 0.5±0.1 and 0.6±0.2 ng/ml in WT and γ3 R225Q mice, respectively and levels achieved during the euglycemic-hyperinsulinemic clamp were 9.4±0.9 and 11.3±1.2 ng/ml, for WT and γ3 R225Q mice respectively (n=6-9)) and obese ob/ob and ob/ob-γ3 R225Q transgenic mice were clamped using an insulin infusion of 75 mU/kg/min due to their extreme insulin-resistant state (Basal plasma insulin levels in ob/ob and ob/ob-γ3 R225Q mice were 15.1±5.6 and 9.3±1.6 ng/ml, respectively levels achieved during the euglycemic-hyperinsulinemic clamp were ob/ob 281.5±60.3 ng/ml and ob/ob-γ3 R225Q 338.1±17.9 ng/ml (n=4)). and ob/ob-γ3 R225Q mice (9.3±0.7 and 11.4±1.8 mM, respectively (n=6-9)). Insulin-stimulated glucose uptake was increased in glycolytic EDL muscle (Fig. 3A) , but not in gastrocnemius muscle (Fig. 3B ) from lean γ3 R225Q transgenic mice under in vivo conditions. Conversely, insulin-stimulated glucose uptake in EDL and gastrocnemius muscle was unchanged between obese ob/ob and ob/ob-γ3 R225Q transgenic mice ( Fig. 3A and 3B ). Glucose concentration, as well as the glucose infusion rate (GIR) was similar at the steady state of the euglycemichyperinsulinemic clamp and after the 2-deoxy-D-[1-
and 3D) and ob/ob mice ( Fig. 3E and 3F ).
Lipid oxidation in isolated EDL muscle:
We have previously reported the AMPKγ3 R225Q mutation increases oleate oxidation in EDL muscle from high-fat fed, but not chow-fed mice (17) . Basal palmitate oxidation was similar in isolated EDL muscle from WT and ob/ob mice (Fig. 4) . There was an effect of the γ3 R225Q transgene to increase palmitate oxidation in EDL muscle from WT and ob/ob mice (Fig. 4) .
Mitochondrial respiration in skeletal muscle: Mitochondrial respiration in freshly dissected
EDL muscles was analyzed using high-resolution respirometry. The leak respiration, which denotes endogenous uncoupling, was similar between the lean and obese non-transgenic and transgenic mice (Fig. 4A ). Mitochondrial respiration at the level of C I, ETS I+II and ETS II was increased in ob/ob versus WT mice (Fig. 4A) . The AMPKγ3 R225Q mutation did not alter the mitochondrial respiration in skeletal muscle from either WT or ob/ob mice. Protein abundance of markers of mitochondrial complexes (NDUFB8, SDHB, UQCRC2, MTCO1
and ATP5A) in gastrocnemius muscle were unaltered between WT and ob/ob mice with or without the γ3 R225Q mutation, except for complex II marker, UQCRC2, which was increased in ob/ob mice compared to WT mice ( Fig. 5B-5F ).
Effects of five days in vivo leptin treatment on food intake, body composition, muscle biochemistry and signaling: Five-day intraperitoneal leptin treatment reduced food intake in lean and obese non-transgenic and transgenic mice, compared to the respective saline-treated mice (Fig. 6A) . Leptin treatment decreased body weight in WT, ob/ob and ob/ob-γ3 R225Q mice compared to the respective saline-treated mice (Fig. 6B) . In contrast, leptin treatment did not significantly decrease body weight in the lean γ3 R225Q transgenic mice (Fig. 6B ).
Body composition was assessed using MRI. Total fat mass was reduced in leptin-treated ob/ob and ob/ob-γ3 R225Q transgenic mice, compared to the respective saline-treated mice (Fig.   6C ). Lean mass was unaltered after saline or leptin treatment in the lean and obese nontransgenic and transgenic mice (Fig. 6D) . Leptin treatment reduced four-hour fasting blood glucose levels in ob/ob-γ3 R225Q transgenic mice, with a similar trend in ob/ob mice (Fig. 6E ).
Gastrocnemius muscle was used for biochemical analysis. Glycogen content was increased in saline-treated lean γ3 R225Q transgenic mice, compared to the WT mice (Fig. 7A) .
Similarly, glycogen content was increased in ob/ob-γ3 R225Q transgenic mice, compared to the ob/ob mice. Glycogen content was not altered in WT and γ3 R225Q transgenic mice after leptintreatment. However, glycogen content was reduced in ob/ob mice compared to saline-treated ob/ob mice after leptin-treatment, but not in ob/ob-γ3 R225Q transgenic mice (Fig. 7A ). GLUT4
protein abundance was unaltered in gastrocnemius muscle from lean and ob/ob mice γ3 R225Q transgenic mice (Fig. 7B ).
Triglyceride content in gastrocnemius muscle was unaltered between saline-and leptintreated WT and γ3 R225Q transgenic mice (Fig. 7C) . While triglyceride content was elevated in ob/ob versus WT mice, the presence of the AMPKγ3 R225Q transgene in the ob/ob mice (ob/ob-γ3 R225Q mice) reduced triglyceride content. Furthermore, leptin treatment reduced triglyceride content in ob/ob mice. However, leptin treatment did not further reduce triglyceride content in gastrocnemius muscle from the ob/ob-γ3 R225Q transgenic mice (Fig. 7C ). DAG and ceramide
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content was assessed in gastrocnemius muscle from saline-and leptin-treated mice. DAG content was increased in ob/ob mice compared to WT mice (Fig. 7D) . DAG content was unaltered in saline or leptin-treated γ3 R225Q transgenic (Fig. 7D) . Ceramide content was unaltered in gastrocnemius muscle from saline-or leptin-treated WT and ob/ob mice WT or γ3 R225Q transgenic mice (Fig. 7E) Fig. 8D and 8E ). ACCα/β protein abundance was increased in lean γ3 R225Q transgenic mice (Fig. 8F) . ACC phosphorylation or abundance was unaltered in leptin-treated lean and obese non-transgenic and transgenic mice, compared to the respective saline-treated mice.
DISCUSSION
Overexpression of key signaling proteins regulating energy metabolism in skeletal muscle can improve metabolic disturbances associated with insulin resistance. Improvements in glucose homeostasis have been achieved by overexpression of either GLUT4 or uncoupling protein 3 in skeletal muscle of mice (25, 32) . AMPK activation by 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) treatment can also improve glucose homeostasis in rodents (5, 7).
Here we tested the hypothesis that expression of a single missense mutation (R225Q) in the AMPKγ3 isoform in skeletal muscle of leptin-deficient ob/ob mice improves glucose and energy homeostasis. We also determined whether leptin treatment would further normalize metabolic disturbances in obesity and whether the effects of AMPK activation on glucose homeostasis are leptin dependent.
Impairments in whole-body glucose metabolism in type 2 diabetic patients are mainly attributed to defects in skeletal muscle glucose uptake and glycogen synthesis (33). Despite severe insulin resistance, AMPK activation promotes GLUT4 translocation and increases glucose uptake directly in skeletal muscle from insulin resistant type 2 diabetic patients (11).
A role for the AMPKγ-subunit in glucose metabolism was first appreciated from studies of Hampshire pigs expressing a naturally occurring dominant mutation (denoted RN-) in the gene encoding the AMPKγ3-isoform (34). This mutation results in an excessive amount of glycogen storage in glycolytic skeletal muscle. In vitro studies in COS7 cells reveal AMPKγ3 R225Q complexes have a higher basal AMPK activity and lack AMP dependence (17).
Thus, the R225Q mutation is a gain-of-function mutation that abolishes allosteric regulation by AMP/ATP, which thereby increases basal AMPK activity.
AMPKγ3
R225Q transgenic mice fed a high fat diet are protected against the development of skeletal muscle insulin resistance (17) . Here we report that in vivo glucose uptake in glycolytic skeletal muscle is increased during a euglycemic-hyperinsulinemic clamp in lean (19) . However, in contrast to our earlier study in fat-fed mice (17) , improvements in muscle biochemistry arising from the AMPKγ3 R225Q mutation were insufficient to ameliorate whole-body insulin resistance in leptin-deficient mice. Thus, a permissive amount of leptin may be required to fully confer the AMPKγ3 R225Q dependent improvements in skeletal muscle insulin-sensitivity.
Several molecular mechanisms account for skeletal muscle glycogen accumulation.
Skeletal muscle GLUT4 protein abundance directly influences the rate of insulin-stimulated glucose uptake and metabolism (35). Moreover, GLUT4 overexpression prevents insulin resistance (26) and glucose intolerance (25) in severely obese diabetic leptin receptordeficient db/db mice, highlighting the importance of skeletal muscle glucose transport in maintaining whole body glucose homeostasis. Skeletal muscle-specific overexpression of glycogen synthase increases glycogen accumulation by an insulin-independent mechanism not involving glucose transport (36), reinforcing the importance of glucose metabolism. Despite the profound increase in glycogen content in chow-fed lean AMPKγ3 R225Q mice, basal and insulin-stimulated glucose uptake in isolated skeletal muscle was similar to wild-type mice (17) . Furthermore, GLUT4 protein abundance was unaltered in gastrocnemius muscle from lean and ob/ob mice WT or AMPKγ3 R225Q transgenic mice. Thus, the increase in glycogen content in AMPKγ3 R225Q transgenic mice is unlikely to arise from constitutive increases in mice, concomitant with a normalization of food intake and a reduction in adiposity.
Moreover, we found that skeletal muscle glycogen content was decreased in leptin-treated ob/ob mice, consistent with effects of leptin to decrease glycogen synthesis in ob/ob mice (47). However, leptin-treatment did not decrease skeletal muscle glycogen content in γ3
R225Q
transgenic lean and ob/ob mice, indicating the γ3 R225Q mutation has a dominant influence on fuel partitioning within skeletal muscle, which may be overcome by hyperleptinemia.
Although the concentration of leptin used in this study was sufficient to improve blood glucose and body weight, higher doses trigger a shift in substrate utilization such as that observed in fat fed AMPKγ3 R225Q mice (17) .
AMPK activation is linked to mitochondrial biogenesis, providing a mechanism for the increased lipid oxidation observed in fat-fed AMPKγ3 R225Q transgenic mice (17) . The increase in mitochondrial respiration in ob/ob mice confirms our previous findings that obesity induces molecular adaptations in glycolytic skeletal muscle to enhance mitochondrial respiration (48) . Figure 7 . Effect of leptin treatment on skeletal muscle glycogen and triglyceride content. Skeletal muscle was dissected from four-hour fasted WT (n=6-11), γ3R225Q (n=8-11), ob/ob (n=5-7) and ob/ob-γ3R225Q (n=9-10) mice 16 hours after the five-day saline or leptin (1 mg/kg) treatment period. Glycogen content (A), GLUT4 protein abundance (B), triglyceride (C), diacylglycerol (D) and ceramide (E) content was measured in gastrocnemius muscle. Saline treatment: black bars; Leptin treatment: white bars. Results are mean±SEM. ***p<0.001 versus saline-treated WT mice; † †p<0.01, † † †p<0.001 versus saline-treated ob/ob mice; ‡p<0.05, ‡ ‡ ‡p<0.001 versus respective saline-treated mice. 190x275mm (96 x 96 DPI)
